Because the drug is in the research and development stage. It has not been put into clinical use, so the harm to people is still unclear. Hengrui Pharma announced that SHR-2004 injection was approved for drug clinical trial. SHR-2004 injection is an innovative biological product 1 independently developed by the company, which is intended to be used for clinical prevention or treatment of arteriovenous thrombosis.
Hengrui Pharma has always been rooted in China, facing the world, focusing on health, focusing on frontier areas, overcoming difficulties and promoting the high-quality development of the pharmaceutical industry. The company regards scientific and technological innovation as the first development strategy. In recent years, the company has continued to invest heavily in R&D, with a cumulative R&D investment of 6.203 billion yuan in 202/KLOC-0, accounting for 23.95% of the operating income, ranking first in the industry. The company has set up R&D centers or branches in the United States, Europe, Japan, Australia and China, and built a large-scale, professional and all-round global R&D team with more than 5,400 people. At present, the company has 1 1 innovative drugs approved for listing, and more than 60 innovative drugs are under clinical research and development. The company has abundant R&D channels, and besides the traditional advantageous tumor fields, it also foresees a wide range of therapeutic fields such as autoimmune diseases, pain management, cardiovascular diseases and metabolic diseases. At the same time, a number of world-class new technology platforms with independent intellectual property rights have been established, providing a strong foundation for innovation and research and development. By the end of 20021,the company had applied for 806 invention patents/kloc-0, 494 PCT patents, 360 valid invention patents in China and 478 patents granted in Europe, America and Japan.